Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07917182). This is a study registration, not published results. Lead sponsor: Chinese University of Hong Kong. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1600 participants (ESTIMATED). Conditions: Alzheimer s Disease, Mild Cognitive Impairment (MCI). Primary outcome measures: Hong Kong Montreal Cognitive Assessment (HK-MoCA) , Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up; Clinical Dementia Rating , Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up; Hong Kong List Learning Test , Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up; Simple Mild Neurocognitive Disorder due to Alzheimer's Disease Risk Test (SMART) , Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up. Brief summary: Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected to become" super-aged" societies. Within Hong Kong specifically, the age- and gender-adjusted prevalence rates of mild and major neurocognitive disorder (NCD) among adults aged 60 years or above have been estimated at 21.8% and 9.7%, respectively. The scale of this burden intensifies considerably within institutional care environments, where roughly seven in ten long-term care (LTC) residents have been identified as having major NCD. Recent local survey data also indicate that severe cognitive impairment affects up to 49.8% of residents aged above 85 years. Given current demographic trajectories, the number of individuals living with dementia in Hong Kong is projected to triple over the next two decades. These trends underscore an urgent, time-sensitive need for scalable, accurate, and population-appropriate tools for the early detection and prognostic stratification of cognitive impairment, tools that must be actionable at the point of care and deployable at population scale. This study aim to generate a large database of cognitive, neuroimaging, plasma biomarkers, lifestyle and psychological information of the subjects who suffered from neurocognitive disorders